That’s a dumb thing to say, wallstarb. Jim Roach commented on the approval chances of Teva’s low-volume Copaxone because I asked him to. Roach gave his personal opinion as an MD, which has absolutely nothing to do with anything Craig Wheeler may have said about when MNTA expects to get FDA approval for generic Lovenox.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.